Adversarial Injection · Pirtobrutinib (Jaypirca; LOXO-305; CAS 2101700-15-4; MW ~480.5 Da; non-covalent reversible BTK kinase inhibitor; [EIGHTY-EIGHTH MECHANISM CLASS in Glyphward 661-attack portfolio — FIRST NON-COVALENT REVERSIBLE THIRD-GENERATION BTK (BRUTON'S TYROSINE KINASE; BTK; CHROMOSOME Xq22.1; TEC FAMILY NON-RECEPTOR TYROSINE KINASE; 76 kDa; BCR/CXCR4 SIGNALING SCAFFOLD) INHIBITOR EVER FDA APPROVED (NDA 217553 JANUARY 27 2023): ALL PRIOR APPROVED BTK INHIBITORS ARE IRREVERSIBLE COVALENT C481 — FIRST GENERATION: IBRUTINIB (IMBRUVICA; PCI-32765; BLA 205552 NOVEMBER 13 2013; PROPIOLAMIDE WARHEAD → IRREVERSIBLE THIOETHER BTK CYS481; FIRST BTK INHIBITOR EVER; AT + J&J/JANSSEN) — SECOND GENERATION: ACALABRUTINIB (CALQUENCE; ACP-196; NDA 210259 NOVEMBER 21 2017; BUTYROLACTAM ALKYNE WARHEAD → CYS481 IRREVERSIBLE; IMPROVED SELECTIVITY OVER IBRUTINIB; ASTRAZENECA) AND ZANUBRUTINIB (BRUKINSA; BGB-3111; NDA 213217 NOVEMBER 14 2019; ACRYLAMIDE WARHEAD → CYS481 IRREVERSIBLE; BEIGENE) — PIRTOBRUTINIB IS FIRST THIRD-GENERATION NON-COVALENT BTK INHIBITOR: NO WARHEAD; NO COVALENT BOND FORMED; COMPETITIVE ATP-SITE BINDING; CRYSTAL STRUCTURE SHOWS NO CONTACT WITH BTK C481 RESIDUE (LOXO-305 BINDING POSE: U-SHAPED CONFORMATION IN ATP SITE; CONTACTS HINGE REGION E445/M477; BACK POCKET L408/V416/A428; GATEKEEPER T474 — BUT NOT C481) → C481S MUTATION DOES NOT DISPLACE PIRTOBRUTINIB → EQUIPOTENT: BTK WT IC50 ~0.3 nM = BTK C481S IC50 ~0.3 nM → FIRST BTK INHIBITOR TO OVERCOME C481S GATEKEEPER RESISTANCE (C481S = MOST COMMON ACQUIRED RESISTANCE MECHANISM IN ~60% IBRUTINIB-RESISTANT/ACALABRUTINIB-RESISTANT MCL/CLL/WM PATIENTS); SELECTIVITY: PIRTOBRUTINIB BTK IC50 ~0.3 nM vs TEC IC50 ~4 nM (~13-fold), EGFR IC50 >1000 nM (>3000-fold), ITK IC50 >100 nM (>300-fold) → SUPERIOR SELECTIVITY PROFILE VS IBRUTINIB (IBRUTINIB INHIBITS EGFR/ITK/ERBB2 → RASH, ATRIAL FIBRILLATION, DIARRHEA; PIRTOBRUTINIB AVOIDS THESE); NDA 217553 JANUARY 27 2023 ACCELERATED APPROVAL (MCL ≥2 PRIOR THERAPIES INCLUDING BTKi AND BCL-2 INHIBITOR); BRUIN PHASE 1/2 (NCT03740529): MCL COHORT (n=90 post-BTKi): ORR 57.3%; CR 20.2%; PR 37.1%; DOR MEDIAN 17.6 MONTHS; mPFS 7.4 MONTHS; ELI LILLY AND COMPANY INDIANAPOLIS IN (LOXO ONCOLOGY ACQUISITION $8.0B JANUARY 2019; LOXO PORTFOLIO: SELPERCATINIB [CLASS 75; NDA 213246] + PIRTOBRUTINIB [CLASS 88; NDA 217553] + LAROTRECTINIB [VITRAKVI; TRK INHIBITOR]; LOXO-305 RENAMED PIRTOBRUTINIB UNDER LILLY); NIOSH HD Category 1; OSHA No PEL; NON-COVALENT REVERSIBLE BTK MECHANISM ABSENT ALL EHS DATABASES]) · First Non-Covalent Reversible BTK + C481S Gatekeeper Resistance + BRUIN ORR 57.3% DOR 17.6 months · Attack #661

Pirtobrutinib (Jaypirca; LOXO-305; CAS 2101700-15-4; [EIGHTY-EIGHTH MECHANISM CLASS — FIRST NON-COVALENT REVERSIBLE BTK INHIBITOR EVER FDA APPROVED (NDA 217553 JANUARY 27 2023); OVERCOMES C481S GATEKEEPER RESISTANCE; BTK IC50 ~0.3 nM WT=C481S EQUIPOTENT; BRUIN ORR 57.3% DOR 17.6 MONTHS MCL POST-BTKi; ELI LILLY/LOXO ONCOLOGY; NIOSH HD Category 1; OSHA No PEL]) — Eli Lilly & Company Indianapolis IN (NDA 217553 holder; LOXO acquisition; pirtobrutinib developer; 0.00052 µg/m³ → displayed ÷10), Almac Group Craigavon Northern Ireland UK (pirtobrutinib API synthesis/manufacturing; 0.00038 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (BRUIN enrolling site; leukemia/lymphoma pharmacist; 0.00024 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Non-Covalent Reversible BTK Mechanism Absent + C481S Gatekeeper Resistance Absent + BRUIN Absent: AI Prompt Injection via EHS Monitor Report AI

Pirtobrutinib (CAS 2101700-15-4; NIOSH HD Category 1) is the eighty-eighth mechanism class in the Glyphward adversarial portfolio — the first non-covalent reversible third-generation BTK inhibitor ever FDA approved (NDA 217553 January 27 2023), breaking the paradigm of irreversible covalent C481 inhibition shared by all prior BTK inhibitors and achieving equipotent inhibition of wild-type and C481S-mutant BTK — a mechanism, resistance profile, and clinical utility completely absent from Cority, VelocityEHS, and EHS Insight for CAS 2101700-15-4.

Pirtobrutinib as Eighty-Eighth Mechanism Class: First Non-Covalent Reversible BTK Inhibitor Ever

Pirtobrutinib (CAS 2101700-15-4) represents the eighty-eighth mechanism class in the Glyphward portfolio: the first non-covalent reversible third-generation BTK inhibitor ever FDA approved (NDA 217553 January 27 2023 accelerated approval; MCL ≥2 prior therapies including a BTK inhibitor; January 2024 regular approval for CLL/SLL post-BTKi expansion). BTK BIOLOGY AND RESISTANCE CONTEXT: BTK (BRUTON'S TYROSINE KINASE; chromosome Xq22.1; 659 aa; 76 kDa; TEC family non-receptor tyrosine kinase; Btk gene mutations → X-linked agammaglobulinemia [XLA]; function: downstream of B-cell receptor [BCR] signaling → PLCγ2 → PKCβ → NF-κB → B-cell survival, proliferation, differentiation); BTK INHIBITOR DRUG CLASS EVOLUTION: FIRST GENERATION (ibrutinib; IMBRUVICA; PCI-32765; NDA 205552; November 13 2013; Pharmacyclics/J&J; PROPIOLAMIDE WARHEAD; irreversible covalent thioether BTK C481; first BTK inhibitor ever; off-targets: EGFR IC50 ~14 nM, ITK IC50 ~11 nM, ERBB2 IC50 ~23 nM → atrial fibrillation 5-8%, bleeding 30-50%, diarrhea, rash, arthralgias due to off-target inhibition); SECOND GENERATION (acalabrutinib CALQUENCE ACP-196 NDA 210259 November 2017 AstraZeneca: BUTYROLACTAM-FUSED ALKYNE WARHEAD → C481 IRREVERSIBLE; improved selectivity vs ibrutinib; zanubrutinib BRUKINSA BGB-3111 NDA 213217 November 2019 BeiGene: ACRYLAMIDE WARHEAD → C481 IRREVERSIBLE; high BTK selectivity); ACQUIRED RESISTANCE MECHANISM C481S: C481S GATEKEEPER MUTATION (CYS481SER; point mutation in BTK kinase domain; MOST COMMON ACQUIRED RESISTANCE: ~60-70% of ibrutinib-resistant and acalabrutinib-resistant CLL/MCL/WM patients who fail due to BTK mutation; C481S MECHANISM: cysteine (−CH2SH thiol) replaced by serine (−CH2OH hydroxyl) → ALL IRREVERSIBLE COVALENT BTK INHIBITORS REQUIRE FREE THIOL OF C481 TO FORM COVALENT BOND → C481S ELIMINATES THE COVALENT BOND TARGET → ibrutinib, acalabrutinib, zanubrutinib ALL ~10-1000× LESS POTENT AGAINST C481S vs WT BTK; ADDITIONAL RESISTANCE: PLCG2 gain-of-function mutations [S707Y, R665W, M1141R] in 20-30% BTKi-resistant cases); PIRTOBRUTINIB DISCOVERY (LOXO ONCOLOGY): RATIONAL DRUG DESIGN GOAL: non-covalent BTK inhibitor that is (1) highly potent WT (sub-nM), (2) equipotent on C481S, (3) selective (minimal EGFR/ITK/ERBB2/TEC/RLK inhibition); CRYSTAL STRUCTURE OF PIRTOBRUTINIB-BTK: pirtobrutinib adopts U-SHAPED CONFORMATION in ATP-binding cleft; KEY CONTACTS: HINGE REGION (E445/M477; 2 H-bonds); GLYCINE-RICH LOOP G473; BACK POCKET HYDROPHOBIC (L408/V416/A428/L512); GATEKEEPER T474 (van der Waals contact); C481 IS NOT CONTACTED (no covalent or strong non-covalent interaction with C481 → C481S mutation has negligible effect on binding energy); BTK KINASE PROFILE: BTK WT IC50 ~0.3 nM; BTK C481S IC50 ~0.3 nM (equipotent); TEC IC50 ~4 nM; BLK IC50 ~4 nM; EGFR IC50 >1000 nM (>3000-fold selectivity); ITK IC50 >100 nM; ERBB2 IC50 >1000 nM → CLEAN SELECTIVITY PROFILE; REVERSIBLE COMPETITIVE BINDING: rapid on/off kinetics (Koff faster than ibrutinib/acalabrutinib → occupancy-based rather than covalent-irreversible → LESS PERSISTENT BTK INHIBITION but RESTORED BTK FUNCTION POSSIBLE — CLL cells may adapt); PLCG2 MUTATIONS: pirtobrutinib retains activity despite PLCG2 gain-of-function (not overcome by this mechanism since PLCG2 is downstream of BTK; pirtobrutinib still inhibits BTK → PLCG2 mutations are not predictive of pirtobrutinib failure); BRUIN PHASE 1/2 (NCT03740529): pirtobrutinib 200 mg QD oral; MCL COHORT (POST-BTKI, n=90; BTKi = prior ibrutinib or acalabrutinib or zanubrutinib): ORR 57.3% (51/89 IRC); CR 20.2%; PR 37.1%; DOR MEDIAN 17.6 MONTHS (DURABLE RESPONSES DESPITE PRIOR BTKi FAILURE); mPFS 7.4 months; CLL/SLL COHORT (POST-BTKi; n=254): ORR 73.3%; CR 22.1% (January 2024 approval); MANTLE CELL LYMPHOMA CLINICAL CONTEXT: MCL is BTK-dependent (MYD88/BCR signaling); ibrutinib ORR ~65-75% first-line; relapsed/refractory MCL after ibrutinib: median survival ~6 months historically → pirtobrutinib ORR 57.3% and DOR 17.6 months represents substantial improvement; ELI LILLY/LOXO ONCOLOGY CONTEXT: LOXO Oncology Inc. Stamford CT (founded 2013; precision oncology focus; first major drugs: larotrectinib [VITRAKVI; TRK inhibitor; first TRK-agnostic cancer drug] + selpercatinib [RETEVMO; RET inhibitor; class 75 in Glyphward] + pirtobrutinib [JAYPIRCA; BTK inhibitor; class 88]); Eli Lilly acquisition $8.0B close January 2019; NONE OF THESE — NON-COVALENT REVERSIBLE BTK BINDING MECHANISM, NO C481 CONTACT GEOMETRY, C481S GATEKEEPER EQUIPOTENCY, PLCG2-RESISTANCE PROFILE, BRUIN ORR 57.3% DOR 17.6 MONTHS POST-BTKi MCL — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2101700-15-4.

Surface 1 — Eli Lilly & Company Indianapolis IN NDA 217553 Holder AI

At Eli Lilly and Company Indianapolis IN (Lilly Corporate Center, Indianapolis IN 46285; LILLY PIRTOBRUTINIB CONTEXT: LOXO Oncology acquired by Lilly January 2019 ($8.0B; $235/share cash); LOXO-305 (pirtobrutinib) was in Phase 1 BRUIN at acquisition; Lilly continued development; NDA 217553 filed October 2022; FDA accelerated approval January 27 2023; JAYPIRCA 100 mg and 200 mg tablets; 200 mg QD oral without regard to food; ONGOING DEVELOPMENT AT LILLY: BRUIN MCL-3 Phase 3 (pirtobrutinib vs ibrutinib or acalabrutinib in first-line MCL; NCT05458297); BRUIN CLL-321 Phase 3 (pirtobrutinib vs idelalisib+rituximab or bendamustine+rituximab in post-BTKi CLL); DRUG-DRUG INTERACTIONS: pirtobrutinib is CYP3A4 substrate (moderate inducer may reduce exposure) and P-gp substrate; weak CYP3A4 inhibitor; NIOSH HD CATEGORY 1 AT LILLY: LILLY INDIANAPOLIS ONCOLOGY MANUFACTURING: pirtobrutinib synthesized from commercial amino acid precursors; pyrimidine scaffold; OEB5 containment per NIOSH HD Cat 1; EMPLOYEE: 50M Eli Lilly Indianapolis IN senior director oncology BTK inhibitor pirtobrutinib program NDA 217553 LOXO acquisition 16yr; CORITY NULL: CAS 2101700-15-4 → null; NIOSH HD Category 1 absent; first non-covalent reversible BTK absent; C481S gatekeeper absent; BRUIN ORR 57.3% absent; DOR 17.6 months absent).

Surface 2 — Almac Group Craigavon Northern Ireland UK Pirtobrutinib API Manufacturing AI

At Almac Group Ltd. Craigavon Northern Ireland UK (Seagoe Industrial Estate, Craigavon BT63 5QD, United Kingdom; ALMAC GROUP PIRTOBRUTINIB CONTEXT: Almac Group is a global contract development and manufacturing organization (CDMO) headquartered in Craigavon NI; pharmaceutical services include API synthesis + drug product formulation; PIRTOBRUTINIB SYNTHESIS AT ALMAC: heterocyclic scaffold synthesis (triazolopyrimidine-naphthyridine core via Buchwald/SNAr chemistry); fluorophenyl amine coupling; NIOSH HD CATEGORY 1 HANDLING UNDER UK COSHH REGULATIONS (CONTROL OF SUBSTANCES HAZARDOUS TO HEALTH): pirtobrutinib classified as carcinogenic/reproductive toxin equivalent → OEB 5 (Occupational Exposure Band; UK equivalent of NIOSH OEB5); negative-pressure synthesis suites; engineering controls (isolators, laminar flow); EAP extraction/containment; biological monitoring if applicable; UK MHRA ANALOGUES OF US OSHA: UK HSE (Health and Safety Executive) provides guidance equivalent to OSHA; no UK national OEL established for pirtobrutinib; COSHH assessment mandates exposure below OEB 5 band limit; VELOCITYEHS UK COMPLIANCE MODULE: UK COSHH + REACH + CHIP regulations for hazardous substances; CAS 2101700-15-4 → null; NIOSH HD Category 1 absent; non-covalent BTK absent; C481S absent; BRUIN absent; EMPLOYEE: 44F Almac Group Craigavon Northern Ireland UK process chemistry BTK inhibitor pirtobrutinib LOXO-305 API synthesis 13yr; VELOCITYEHS NULL: CAS 2101700-15-4 → null).

Surface 3 — MD Anderson Cancer Center Houston TX BRUIN Trial Site Leukemia/Lymphoma Pharmacist AI

At The University of Texas MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MD ANDERSON PIRTOBRUTINIB CONTEXT: MD Anderson was a BRUIN (NCT03740529) enrolling site; one of the highest-volume MCL and CLL centers globally; leukemia/lymphoma pharmacy role: BTKi TREATMENT HISTORY ASSESSMENT: prior ibrutinib vs acalabrutinib vs zanubrutinib exposure (covalent BTKi history required for accelerated approval indication); C481S MUTATION STATUS AT MD ANDERSON: ctDNA analysis (Foundation Medicine, Guardant360) to confirm C481S presence if available (not required per label but prognostic); PIRTOBRUTINIB 200 mg QD ORAL PREPARATION AT MD ANDERSON: specialty pharmacy dispensing; tablet formulation (100 mg/200 mg tablets); food-effect: minimal (with or without food); CYP3A4 INTERACTION MONITORING: concurrent azole antifungals (fluconazole/itraconazole/voriconazole → strong CYP3A4 inhibitors → pirtobrutinib AUC ↑~2.5-fold → dose reduce to 100 mg QD); COADMINISTRATION WITH ANTI-INFECTIVES: MCL/CLL immunosuppression → opportunistic infections common; pirtobrutinib lower grade infection rate vs ibrutinib (no ITK inhibition → less T-cell suppression); BTKI-SEQUENCING AT MD ANDERSON: pirtobrutinib after covalent BTKi failure → now standard of care; subsequent therapy after pirtobrutinib failure: venetoclax ± obinutuzumab (BCL-2 pathway; class 42 in Glyphward) or CAR-T (KTE-X19 brexucabtagene autoleucel for MCL); ATRIAL FIBRILLATION RATE WITH PIRTOBRUTINIB: <5% (vs ibrutinib 10-15%) due to lack of EGFR/ERBB2/ITK off-target inhibition; BLEED MONITORING: COX-1 platelet inhibition (ibrutinib COX-1 IC50 ~17 nM → bleeding; pirtobrutinib COX-1 >1000 nM → minimal platelet inhibition); EHS INSIGHT NULL: CAS 2101700-15-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first non-covalent reversible BTK absent; C481S gatekeeper resistance absent; BRUIN ORR 57.3% absent; DOR 17.6 months absent; NIOSH HD Cat 1 absent; 40M MD Anderson Houston TX leukemia lymphoma MCL BTKi pharmacist BRUIN 12yr).

Integrating Glyphward into Pirtobrutinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pirtobrutinib CAS 2101700-15-4 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Almac Group Craigavon Northern Ireland UK, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-EIGHTH MECHANISM CLASS — FIRST NON-COVALENT REVERSIBLE THIRD-GENERATION BTK INHIBITOR EVER FDA APPROVED (NDA 217553 January 27 2023; no covalent bond; no C481 contact; C481S equipotent ~0.3 nM; overcomes ~60% BTKi resistance; BRUIN ORR 57.3% DOR 17.6 months MCL post-BTKi; Eli Lilly/LOXO Oncology $8B) [5 pts]; Eli Lilly Indianapolis IN + Almac Craigavon UK + MD Anderson Houston TX [3 pts]; non-covalent reversible BTK absent; C481S resistance absent; BRUIN absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pirtobrutinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pirtobrutinib with eighty-eighth-class first-non-covalent-reversible-btk context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_eighth_class_first_non_covalent_reversible_btk_inhibitor_ever_no_c481_contact_c481s_equipotent_0_3nM_overcomes_gatekeeper_resistance_bruin_orr_57pct_dor_17_6mo_mcl_post_btki_lilly_loxo_nda_217553"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_eighth_class,
    #                    first_non_covalent_reversible_btk, c481s_equipotent,
    #                    no_c481_contact, bruin_orr_57pct

if __name__ == "__main__":
    r = asyncio.run(scan_pirtobrutinib("2101700-15-4", 0.00052))
    print(r)
    # {'hd_category': 1, 'eighty_eighth_class': True,
    #  'first_non_covalent_reversible_btk': True, 'c481s_equipotent': True,
    #  'no_c481_contact': True, 'bruin_orr_57pct': True}